Analysts/Institutional Investor Meet/Con. Call Updates

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com September 10, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code:532843 Sub: Transcript of Investors / Analyst’s meet under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Madam/Sir, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed transcript of Investors / Analysts’ meet held on Friday, September 4, 2026, on the recent developments. The same has been made available on the website of the Company at below hyperlink: - earnings call transcript for the conference call september 2026 The date and time of occurrence of event is Friday, September 04, 2026 at 1:50 PM (IST) This is for your kind information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer ICSI Membership: A14783 Encl: a/a FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 “Fortis Healthcare Limited” Conference Call” September 04, 2026 MANAGEMENT: DR. ASHUTOSH RAGHUVANSHI – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – FORTIS HEALTHCARE LIMITED MR. VIVEK GOYAL – CHIEF FINANCIAL OFFICER – FORTIS HEALTHCARE LIMITED MR. ANURAG KALRA – SENIOR VICE PRESIDENT, INVESTOR RELATIONS – FORTIS HEALTHCARE LIMITED MR. AMIT MAHENDRU – GENERAL MANAGER - M&A AND INVESTOR RELATIONS – FORTIS HEALTHCARE LIMITED MR. DILIP KADAMBI – GROUP CHIEF FINANCIAL OFFICER – IHH HEALTHCARE Page 1 of 14 Fortis Healthcare Limited September 04, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Conference Call hosted by Fortis Healthcare and IHH Healthcare Berhad. As a reminder, all participant lines will be in the listen- only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. I now hand the conference over to Dr. Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare. Thank you, and over to you, sir. Ashutosh Raghuvanshi: Thank you. Good morning and good afternoon, everyone. Thank you for taking time to join us on this call today. I have along with me our Group CFO, Mr. Vivek Goyal of Fortis Healthcare, as well as Mr. Anurag Kalra and Amit Mahendru from the Investor Relations team. We also have the IHH Group CFO, Mr. Dilip Kadambi, on the call. And the purpose of speaking with you today jointly is primarily to address any clarifications you might have on the recent developments related to the Delhi High Court order that was released on this Monday. I hope all of you would have had a chance to read our stock exchange announcement on this matter. The current order, which is a 200-page order by the court, has directed the appointment of forensic auditor and provided a scope to the audit to be undertaken. While we can address any questions you might have, I want to highlight upfront that the current order in no way changes, limits, or impedes any of our strategic or operational plans, including those related to our investment, capex, bed expansion, and our initiatives on the M&A front. We are currently in deliberation with our legal counsels on the best way forward, but at this point of time, we will fully abide by the directions of Honorable Court in cooperating with the said forensic exercise. Those were my brief opening statements to set the context. We can now move to the question-and-answer session. Anurag Kalra: Can I please request the moderator to begin the Q&A, please? Moderator: Thank you very much. We will now begin the question-and-answer session. The first question is from the line of Neha Manpuria from Bank of America. Please go ahead. Neha Manpuria: Yeah. Thanks for taking my question. First question, Dr. Raghuvanshi, on the scope of the forensic audit, would this just be the RHT transaction that Fortis did, or would this also include IHH’s investment into Fortis, if you could give us some color on that? And based on our legal counsel, what could be the duration of this forensic audit based on past precedents? Ashutosh Raghuvanshi: Yes, Neha. The scope of audit covers a few things, as mentioned in the order. One is the reconstruction of complex evolution of FHHPL, which is the promoter entity, the erstwhile promoter entity, which has nothing to do with FHL. Through this entity, they were holding shares in FHL. So during the period of ‘18 to ‘26, they would look at this. This is the main contention of the matter. Wherein, despite assurances being given to the court by the erstwhile promoters that they Page 2 of 14 Fortis Healthcare Limited September 04, 2026 have adequate assets to cover the arbitral award given to Daiichi, the key assets were their shares in Fortis. So, these shares were eventually divested to other third parties and not to IHH/NTK. The second part of the forensic audit is the examination of acquisition of controlling stake in FHL by IHH/NTK, including approvals, filing, etc, related to the such acquisition, and the subsequent utilization of investment amounts towards the acquisition of healthcare assets from RHT Health Trust in Singapore. But as you're aware that, as far as these shares were concerned, these were not bought shares, but this was a primary issuance, which had happened, and so we are surprised that such a thing has been included in the scope. The third thing which is there in the scope is the examination of any role if any, of FHL and its officers and key managerial personnel in processing and approving the unencumbered share dissipation transaction of the erstwhile promoters. We, again, believe that this is not something in which company was involved in any way or had any role to play because this was between the erstwhile promoters and the concerned banks. And the last part of this scope is the examination of the role of all 17 banks and financial institutions in dissipation of the said assets. So, that is the large scope which has been ordered. And as far as duration is concerned, it has been written that in 4 weeks the auditor needs to send its questionnaire of the information requisition, followed by 2 weeks to respond, and then 6 months to come up with a report. That's the timeline which has been set by the court. Neha Manpuria: Okay. And thereafter, this would again be heard by the High Court, or I mean, what would be what could be a potential outcome of these audits? I mean, depending -- I know there are a lot of variables, but just trying to understand the worst case that could come out in your view. Ashutosh Raghuvanshi: Yeah. So, the audit findings obviously will be presented to the court. But as I have already mentioned, though it would be premature to comment on this stage, but we believe Fortis has been in complete compliance with the law at all the times. And hence, at this juncture, we don't foresee any significant or material adverse results from the audit. Neha Manpuria: Understood. And my second question is... Dilip Kadambi: If I may Yeah. And may if I may add there, Neha, this is Dilip here. From an IHH standpoint... Neha Manpuria: Sorry, sir. Yeah, Dilip. Dilip Kadambi: From an IHH standpoint, you must recall that we participated in a process that was run by the independent directors appointed by then investors, who were activist investors. And these independent directors ran a process, a fair and transparent process, where there were other bidders as well. And as part of that, as Dr. Raghuvanshi mentioned, we invested money into [Showing first 8,000 characters — download PDF for full document]